Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03928704 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis
A Phase 3 study of Nonradiographic Axial Spondyloarthritis, sponsored by UCB Biopharma SRL.
- Completed
- Registry status
- Phase 3
- Development phase
- 274
- Enrollment target
- 20
- Study locations
NCT03928704 is a Phase 3 study of Nonradiographic Axial Spondyloarthritis that has completed, run by UCB Biopharma SRL. The registered enrollment target is 274 participants. The trial reports 20 study locations across 11 states.
The verdict
NCT03928704, a Phase 3 study of Nonradiographic Axial Spondyloarthritis, has completed, sponsored by UCB Biopharma SRL.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 274 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to demonstrate the efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared to placebo in the treatment of subjects with active nonradiographic axial spondyloarthritis (nr-axSpA).
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Bimekizumab
Study Locations (20)
Other
- As0010 40004 - Brussels
- As0010 40003 - Genk
- As0010 40001 - Ghent
- As0010 40002 - Merksem
- As0010 40006 - Plovdiv
- As0010 40007 - Plovdiv
Arizona
- As0010 50131 - Mesa
- As0010 50052 - Phoenix
- As0010 50062 - Sun City
Florida
- As0010 50059 - Ormond Beach
- As0010 50056 - Sarasota
Texas
- As0010 50057 - Dallas
- As0010 50036 - Mesquite
California
- As0010 50060 - Upland
Maryland
- As0010 50015 - Hagerstown
Missouri
- As0010 50016 - St Louis
Oregon
- As0010 50055 - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 274 participants |
| Start Date | 2019-04-25 |
| Est. Completion | 2023-04-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03928704
The ClinicalTrials.gov registry entry for NCT03928704 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 274 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biopharma SRL, which has 82 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Nonradiographic Axial Spondyloarthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03928704 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT03928704 about?
NCT03928704 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis". The purpose of the study is to demonstrate the efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared to placebo in the treatment of subjects with active nonradiographic axial spondyloarthritis (nr-axSpA).
What is the current status of trial NCT03928704?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 274 participants. The study started on 2019-04-25. Estimated completion is 2023-04-17.
What conditions does trial NCT03928704 study?
This clinical trial studies the following conditions: Nonradiographic Axial Spondyloarthritis.
What interventions are being tested in trial NCT03928704?
The interventions under investigation include: Placebo (OTHER), Bimekizumab (DRUG).
Who is sponsoring clinical trial NCT03928704?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03928704 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.